Effects of Rosuvastatin on Apolipoprotein J in Balloon-Injured Carotid Artery in Rats

Arq Bras Cardiol. 2018 Oct;111(4):562-568. doi: 10.5935/abc.20180163. Epub 2018 Sep 21.
[Article in English, Portuguese]

Abstract

Background: Restenosis after percutaneous coronary intervention in coronary heart disease remains an unsolved problem. Clusterin (CLU) (or Apolipoprotein [Apo] J) levels have been reported to be elevated during the progression of postangioplasty restenosis and atherosclerosis. However, its role in neointimal hyperplasia is still controversial.

Objective: To elucidate the role Apo J in neointimal hyperplasia in a rat carotid artery model in vivo with or without rosuvastatin administration.

Methods: Male Wistar rats were randomly divided into three groups: the control group (n = 20), the model group (n = 20) and the statin intervention group (n = 32). The rats in the intervention group were given 10mg /kg dose of rosuvastatin. A 2F Fogarty catheter was introduced to induce vascular injury. Neointima formation was analyzed 1, 2, 3 and 4 weeks after balloon injury. The level of Apo J was measured by real-time PCR, immunohistochemistry and western blotting.

Results: Intimal/medial area ratio (intimal/medial, I/M) was increased after balloon-injury and reached the maximum value at 4weeks in the model group; I/M was slightly increased at 2 weeks and stopped increasing after rosuvastatin administration. The mRNA and protein levels of Apo J in carotid arteries were significantly upregulated after rosuvastatin administration as compared with the model group, and reached maximum values at 2 weeks, which was earlier than in the model group (3 weeks).

Conclusion: Apo J served as an acute phase reactant after balloon injury in rat carotid arteries. Rosuvastatin may reduce the neointima formation through up-regulation of Apo J. Our results suggest that Apo J exerts a protective role in the restenosis after balloon-injury in rats.

Publication types

  • Evaluation Study

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects*
  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Blotting, Western
  • Carotid Arteries / drug effects
  • Carotid Arteries / pathology
  • Carotid Artery Injuries / drug therapy*
  • Carotid Artery Injuries / etiology
  • Carotid Artery Injuries / pathology
  • Clusterin / analysis
  • Clusterin / drug effects*
  • Coronary Restenosis / drug therapy*
  • Coronary Restenosis / etiology
  • Coronary Restenosis / pathology
  • Enzyme-Linked Immunosorbent Assay
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Immunohistochemistry
  • Male
  • Protective Agents / pharmacology
  • Random Allocation
  • Rats, Wistar
  • Real-Time Polymerase Chain Reaction
  • Reproducibility of Results
  • Rosuvastatin Calcium / pharmacology*
  • Time Factors
  • Treatment Outcome
  • Tunica Intima / drug effects
  • Tunica Intima / pathology
  • Tunica Media / drug effects
  • Tunica Media / pathology

Substances

  • Anticholesteremic Agents
  • Clusterin
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Protective Agents
  • Rosuvastatin Calcium

Grants and funding

This work was funded by the Health and Family Planning Commission, Science and Technology of Tianjin, (Award Nº. 2015KR07), and the Tianjin Health Industry (Award Nº. 13KG131).